Global X Genomics & Biotechnology ETF (GNOM)
| Assets | $94.83M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 1.42M |
| Dividend (ttm) | $0.65 |
| Dividend Yield | 1.00% |
| Ex-Dividend Date | Jun 29, 2026 |
| Payout Frequency | Semi-Annual |
| Payout Ratio | n/a |
| Volume | 334 |
| Open | 65.15 |
| Previous Close | 65.13 |
| Day's Range | 64.86 - 66.51 |
| 52-Week Low | 36.00 |
| 52-Week High | 66.88 |
| Beta | 1.17 |
| Holdings | 52 |
| Inception Date | Apr 5, 2019 |
About GNOM
Fund Home PageThe Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that is based on the Solactive Genomics index. The fund tracks an index of global biotech equities, selected and weighted by market cap. GNOM was launched on Apr 5, 2019 and is issued by Global X.
Top 10 Holdings
46.44% of assets| Name | Symbol | Weight |
|---|---|---|
| Twist Bioscience Corporation | TWST | 5.98% |
| Guardant Health, Inc. | GH | 5.77% |
| 10x Genomics, Inc. | TXG | 5.44% |
| Natera, Inc. | NTRA | 4.90% |
| Illumina, Inc. | ILMN | 4.81% |
| BioMarin Pharmaceutical Inc. | BMRN | 4.09% |
| Bio-Techne Corporation | TECH | 4.06% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 3.85% |
| Vertex Pharmaceuticals Incorporated | VRTX | 3.80% |
| Moderna, Inc. | MRNA | 3.74% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 29, 2026 | $0.05789 | Jul 7, 2026 |
| Dec 30, 2025 | $0.59121 | Jan 7, 2026 |
| Jun 27, 2025 | $0.03312 | Jul 7, 2025 |
| Dec 30, 2021 | $0.02603 | Jan 7, 2022 |
| Dec 30, 2020 | $0.12961 | Jan 8, 2021 |
Performance
GNOM had a total return of 76.63% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.07%.
News
Global X Announces Five ETF Reverse Stock Splits
NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Global X Management Company, LLC ("Global X"), the New York-based provider of exchange traded funds (ETFs), today announced reverse splits of the following five...
Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4%...
Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says
Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.